Lumos Diagnostics, a subsidiary of Planet Innovation, announced this week it acquired RPS Diagnostics for an undisclosed price. RPS develops, manufactures and markets rapid, point-of-care diagnostic tests for a variety of infectious diseases and inflammatory conditions.
The merged company will be called Lumos Diagnostics. This deal adds RPS’s FebriDx test, a rapid, in-office test that provides clinicians with a rapid assessment of the body’s immune response to an acute respiratory infection. Combining RPS’ biomarker technology and Lumos’ reader-based platform will create a strong pipeline of products.
This deal caps off a relatively busy month for the laboratories, MRI and dialysis sector. It’s a pretty quiet field, but there have been four deals this month, double that compared with May 2018. At the beginning of the month, PathGroup purchased Pathologists Bio-Medical Laboratories, which offers pathology services in a variety of areas such as hematopathology and neuropathology. The combined company will include more than 120 pathologists, representing every sub-specialty and will include more than 1,800 employees working with more than 75 hospitals and thousands of physicians across the United States.
The only deal with a disclosed price, as Meridian Bioscience, Inc. took over GenePOC’s molecular diagnostics business portfolio for $50 million, plus another $70 million in possible milestones and sale thresholds. GenPOC’s revogene biomarker platform will complement Meridian’s existing molecular platform, especially in advancing its goal to provide gastrointestinal disease and core respiratory illness diagnostics solutions.
Across the Atlantic, a French investment firm, Duomodiag Sarl, bought Diesse Diagnostica, an Italy-based diagnostics company, from Orphée SA, the Swiss subsidiary of diagnostics group PZ Cormay SA. Diesse develops in vitro diagnostic (IVD) systems for the diagnosis of infectious and autoimmune diseases, and hematology systems to test for inflammation. It provides services in more than 100 countries.